MedPath

Radiomics Analysis of Focal Liver Lesions Based on Contrast-Enhanced Ultrasound Imaging

Recruiting
Conditions
Contrast-enhanced Ultrasound
Focal Liver Lesions
Registration Number
NCT04682886
Lead Sponsor
Ping Liang
Brief Summary

Contrast-enhanced ultrasound (CEUS) substantially improves the potential of ultrasound (US) for the identification and characterization of focal liver lesions (FLLs). Compared to contrasted-enhanced MRI and CT, it has some unique advantages, such as the absence of ionizing radiation, and easy operability and repeatability. However, the efficacy of CEUS in diagnosing liver lesions is challenged by several factors including being highly dependent on doctor's experience, low signal-to-noise ratio, and low interobserver agreement. Therefore, it is a beneficial attempt to construct an intelligent CEUS diagnosis system using digital information technology. This study aims to collect standard data of CEUS cines recordings and develop deep learning model for accurate segmentation, detection and classification of liver lesions.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
5000
Inclusion Criteria
  1. patients with a solid liver tumor visible during routine ultrasound and received CEUS.
  2. disease history and standard of reference of the lesions can be acquired
Exclusion Criteria
  1. hypersensitivity for ultrasound contrast media
  2. pregnant or lactating patients
  3. previously treated lesions or local relapse from previously treated lesions
  4. diffuse tumors

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
specificitythrough study completion, an average of 7 year

diagnosis specificity of intelligent CEUS analysis

AUC valuethrough study completion, an average of 7 year

Area under the receiver operating characteristic (ROC) curve (AUC)

sensitivitythrough study completion, an average of 3 year

diagnosis sensitivity of intelligent ultrasound analysis

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chinese PLA General Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath